The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...